- 专利标题： TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
-
申请号： US16966961申请日： 2019-02-11
-
公开(公告)号： US20210361662A1公开(公告)日： 2021-11-25
- 发明人: Mark W. Embrey , Timothy John Hartingh , Marc Labroli , Izzat T. Raheem
- 申请人： Merck Sharp & Dohme Corp.
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 国际申请： PCT/US2019/017409 WO 20190211
- 主分类号： A61K31/53
- IPC分类号： A61K31/53 ; C07D471/18 ; C07D498/18 ; A61K31/513 ; A61K31/7068 ; A61K31/427 ; A61K31/635 ; A61K31/4418 ; A61K31/675 ; A61K31/505 ; A61K31/52 ; A61K31/5365
摘要：
The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
公开/授权文献
信息查询
